COMP <GO>
STLN vs AHCO // REVENUE GROWTH (YOY)
Starling Oncology Inc. (NASDAQ) VS. AdaptHealth Corp. (NASDAQ) • 15-METRIC TALLY: STLN 4
— AHCO 4
▲ REVENUE GROWTH (YOY) LEADER: STLN
LAST: $6.65 (+0.15%) • MKT CAP: $677.7M
revenue-growth
27.80%
LAST: $5.93 (-1.66%) • MKT CAP: $808.5M
revenue-growth
-0.50%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (STLN VS. AHCO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | STLN | AHCO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 18.80% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 2.20% | -37.20 | AHCO | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 6.1x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -4.10% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -7.20% | 2.80% | -10.00 | AHCO | /operating-margins <GO> |
| Net Profit Margin | 68.00% | -2.20% | +70.20 | STLN | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 27.80% | -0.50% | +28.30 | STLN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.58 | 0.79 | +1.79 | STLN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 4/9 | -1.00 | AHCO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.8 | 48.1 | +3.70 | STLN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $677.7M | $808.5M | -$130.8M | AHCO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | STLN REV | AHCO REV | STLN GROSS % | AHCO GROSS % | STLN FCF | AHCO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $502.7M | $3.24B | — | 18.8% | -$27.8M | $219.4M |
| FY 2024 | $393.4M | $3.26B | — | 20.9% | -$30.3M | $235.8M |
| FY 2023 | $324.2M | $3.20B | — | — | -$36.3M | $480.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
STLN // BETA —
AHCO // BETA —